Pseudomonas aeruginosa bacteriophage pse-AEP-4 and use thereof for inhibiting proliferation of Pseudomonas aeruginosa
Inventors
Yoon, Seong Jun • JUN, Soo Youn • Son, Jee Soo • Paik, Hyoun Rok • SHIN, Hee Jeong • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11497216-B2
Publication Date
2022-11-15
Expiration Date
Abstract
The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-4 as an active ingredient.
Core Innovation
The invention relates to Podoviridae bacteriophage Pse-AEP-4 (KCTC 13166BP) isolated from nature and characterized by a genome represented by SEQ ID NO: 1. The description frames the work in the context of antibiotic resistance and the need for phage-based countermeasures. Pse-AEP-4 is described as having ability to specifically kill Pseudomonas aeruginosa.
The solution is to administer a composition comprising Podoviridae bacteriophage Pse-AEP-4 to an animal other than a human. The invention is directed to suppressing diseases caused by a bacterial strain of Pseudomonas aeruginosa and alleviating pathological condition of the diseases. The diseases targeted are urinary tract infections, wound infections, bacteremia, or endocarditis caused by a bacterial strain of Pseudomonas aeruginosa.
The document further characterizes Pse-AEP-4 morphology consistent with Podoviridae and provides genome characterization including circular genome and open reading frames (ORFs). The genome is described as related to Pseudomonas aeruginosa phage LUZ19 while showing differences in topology and ORF composition. Experimental support is provided for strain-specific killing of Pseudomonas aeruginosa strains, including suppression and alleviation of infection-associated pathology in in vivo models.
Claims Coverage
The partial content includes one independent claim. It contains four main inventive components: the specific non-human animal administration method, the defined Podoviridae bacteriophage Pse-AEP-4 composition characterized by SEQ ID NO: 1 and deposited as KCTC 13166BP, the ability to specifically kill Pseudomonas aeruginosa, and the disease indications limited to urinary tract infections, wound infections, bacteremia, and endocarditis caused by Pseudomonas aeruginosa.
Non-human animal administration to suppress and alleviate Pseudomonas aeruginosa disease
A method of suppressing diseases caused by a bacterial strain of Pseudomonas aeruginosa and alleviating pathological condition of the diseases comprising administering to an animal other than a human a composition comprising Podoviridae bacteriophage Pse-AEP-4.
Podoviridae bacteriophage Pse-AEP-4 specifically killing defined Pseudomonas aeruginosa strain
The composition comprises Podoviridae bacteriophage Pse-AEP-4 which has an ability to specifically kill the bacterial strain of Pseudomonas aeruginosa.
Genome sequence and deposit definition for Pse-AEP-4
Pse-AEP-4 has the genome represented by SEQ ID NO: 1 and is deposited as accession number KCTC 13166BP.
Disease indications limited to urinary tract infections, wound infections, bacteremia or endocarditis
The diseases are urinary tract infections, wound infections, bacteremia or endocarditis.
Overall, the claim scope is directed to administering a composition containing Podoviridae bacteriophage Pse-AEP-4 that specifically kills a Pseudomonas aeruginosa strain, where the phage is defined by SEQ ID NO: 1 and accession number KCTC 13166BP, for suppressing and alleviating specified disease indications in an animal other than a human.
Stated Advantages
Reduced impact on commensal bacteria relative to antibiotics.
Documented Applications
Urinary tract infections, wound infections, bacteremia, and endocarditis caused by a bacterial strain of Pseudomonas aeruginosa.
Interested in licensing this patent?